Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
12
Today In Oncology
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
The Wistar Institute Names New President and Chief Executive Officer
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
HER2-Negative Advanced Gastric Cancers First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo